Transpl Int Transplant International Transpl Int 1432-2277 Frontiers Media S.A. 12843 10.3389/ti.2024.12843 Health Archive Retraction Retraction: Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements Transplant International Editorial Office XXX Transplant International Editorial Office *

Approved by: Thierry Berney, University of Geneva, Switzerland

 *Correspondence: Transplant International Editorial Office, tieditorialoffice@frontierspartnerships.org 05 03 2024 2024 37 12843 13 02 2024 23 02 2024 Copyright © 2024 Transplant International Editorial Office. 2024 Transplant International Editorial Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Retraction of the Review Article Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements by Baiguera S, Jungebluth P, Mazzanti B, Macchiarini P. (2012). Transpl. Int. 2012; 25: 369-82. doi: 10.1111/j.1432-2277.2011.01426.x

Transplant International published in 2012 a review paper [1], in which another article from the same authors was cited [2]. This article had been published in the Lancet in 2008 and was very recently retracted for demonstrated falsification [3]. The falsification had been confirmed in a decision by the Swedish National Board for Assessment of Research Misconduct [4].

Briefly, the paper retracted by the Lancet described the allegedly successful transplantation of a tissue-engineered tracheal segment, reporting that “the graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months” [2]. The conclusions of the investigation by the Swedish National Board for Assessment of Research Misconduct found that this statement constituted falsification [4].

The review article [1] was accepted and published in Transplant International based on its perceived quality and the supposed merits of the authors’ work. In this review, the authors stated that “(tissue engineering) has already provided functional tissue and organ human replacement” (sic), citing to support this point the retracted Lancet article [2] that they knew contained falsified data.

We are therefore retracting this review article.

Thierry Berney.

Transplant International editor-in-chief.

References Baiguera S Jungebluth P Mazzanti B Macchiarini P . Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements. Transpl Int (2012) 25:369–82. 10.1111/j.1432-2277.2011.01426.x Macchiarini P Jungebluth P Go T Asnaghi MA Rees LE Cogan TA Clinical Transplantation of a Tissue-Engineered Airway. Lancet (2008) 372:2023–30. 10.1016/S0140-6736(08)61598-6 The Editors of The Lancet. Retraction: Clinical Transplantation of a Tissue-Engineered Airway. Lancet (2023) 402:1510. 10.1016/S0140-6736(23)02341-3 Swedish National Board for Assessment of Research Misconduct. Decision Regarding Research Misconduct. Ref 3.2-22/0092 (2023). Available at: https://npof.se/wp-content/uploads/2023/10/Decision-in-case-3.2-22-0092_web.pdf (Accessed December 15, 2023).